|
gptkbp:instanceOf
|
gptkb:drug
immunotherapy
|
|
gptkbp:approvedBy
|
gptkb:FDA
1996
|
|
gptkbp:ATCCode
|
gptkb:L03AX13
|
|
gptkbp:brand
|
gptkb:Copaxone
|
|
gptkbp:CASNumber
|
147245-92-9
|
|
gptkbp:chemicalFormula
|
C25H45N5O13
|
|
gptkbp:contraindication
|
hypersensitivity to glatiramer acetate
|
|
gptkbp:developedBy
|
gptkb:Teva_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
short (minutes)
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
glatiramer acetate
|
|
gptkbp:indication
|
relapsing-remitting multiple sclerosis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
modulates immune processes
|
|
gptkbp:metabolism
|
hydrolysis
|
|
gptkbp:notRecommendedFor
|
primary progressive multiple sclerosis
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescribes
|
gptkb:neuroscientist
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
injection site reaction
chest pain
palpitations
flushing
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:usedFor
|
multiple sclerosis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:Copaxone
|
|
gptkbp:bfsLayer
|
6
|